Fullmakter til Ola Røthe re. Ekstraordinær Generalforsamling 11 oktober

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Det meddeles herved at Ola Røthe har mottatt fullmakter til å stemme for totalt 2 056 508 aksjer, som utgjør 7,51 % av selskapets totale antall utstedte aksjer, på selskapets ekstraordinære generalforsamling 11. oktober 2010. 

About Us

NattoPharma ASA is a Norwegian nutraceutical company with exclusive rights to sell and market the branded ingredient MenaQ7®, Natural Vitamin K2. We are investing in clinical science to always be at the cutting edge on vitamin K2 research and hold an exclusive R&D alliance with VitaK BV, the world’s leading experts in research and scientific documentation of K vitamins. NattoPharma is building competitive advantage through focus on IPR. We have granted patents and pending related to relevant indications and market segments, and will continue to develop our IPR portfolio to offer value for our customers in the health care, supplement and functional food markets. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. According to the World Health Organization (WHO) cardiovascular diseases and osteoporosis are the two biggest global health care problems. The NattoPharma staff consists of highly professional people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. Our sales and marketing department has extensive experience in international markets. MenaQ7ᆴ provides vitamin K2 as menaquinone-7 (MK-7), the highly pure and bio-available form of natural vitamin K2, produced to our pharmaceutical standards and validated by the Vitamin K experts at VitaK, the University of Maastricht. MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.